Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis

2008 ◽  
Vol 71 (1) ◽  
pp. 64-70 ◽  
Author(s):  
Jing Li ◽  
Soren M. Bentzen ◽  
Jialiang Li ◽  
Markus Renschler ◽  
Minesh P. Mehta
Keyword(s):  
Quality Of Life ◽  
Brain Metastasis ◽  
Whole Brain Radiotherapy ◽  
Neurocognitive Function ◽  
Whole Brain ◽  
Brain Radiotherapy

scholarly journals Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life

BMC Cancer ◽  
2007 ◽  
Vol 7 (1) ◽  
Author(s):  
Raffaele Addeo ◽  
Michele Caraglia ◽  
Vincenzo Faiola ◽  
Elena Capasso ◽  
Bruno Vincenzi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Brain Metastasis ◽  
Whole Brain Radiotherapy ◽  
Concomitant Treatment ◽  
Whole Brain ◽  
Brain Radiotherapy

scholarly journals A Dutch phase III randomized multicenter trial: whole brain radiotherapy vs. stereotactic radiotherapy for 4-10 brain metastases

2021 ◽  
Author(s):  
Dianne Hartgerink ◽  
Anna Bruynzeel ◽  
Danielle Eekers ◽  
Ans Swinnen ◽  
Coen Hurkmans ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Brain Metastases ◽  
Survival Rates ◽  
Whole Brain Radiotherapy ◽  
Phase Iii ◽  
Whole Brain ◽  
Brain Radiotherapy ◽  
One Year

Abstract Background The clinical value of whole brain radiotherapy (WBRT) for brain metastases (BM) is a matter of debate due to the significant side effects involved. Stereotactic radiosurgery (SRS) is an attractive alternative treatment option that may avoid these side effects and improve local tumor control. We initiated a randomized trial (NCT02353000) to investigate whether quality of life is better preserved after SRS compared with WBRT in patients with multiple brain metastases. Methods Patients with 4 to 10 BM were randomized between the standard arm WBRT (total dose 20 Gy in 5 fractions) or SRS (single fraction or 3 fractions). The primary endpoint was the difference in quality of life (QOL) at three months post-treatment. Results The study was prematurely closed due to poor accrual. A total of 29 patients (13%) were randomized, of which 15 patients have been treated with SRS and 14 patients with WBRT. The median number of lesions were 6 (range, 4-9) and the median total treatment volume was 13.0 cc 3 (range, 1.8-25.9 cc 3). QOL at three months decreased in the SRS group by 0.1 (SD=0.2), compared to 0.2 (SD=0.2) in the WBRT group (p=0.23). The actuarial one-year survival rates were 57% (SRS) and 31% (WBRT) (p=0.52). The actuarial one-year brain salvage-free survival rates were 50% (SRS) and 78% (WBRT) (p=0.22). Conclusion In patients with 4 to 10 BM, SRS alone resulted in one-year survival for 57% of patients while maintaining quality of life. Due to the premature closure of the trial, no statistically significant differences could be determined.

Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial

2017 ◽  
Vol 20 (2) ◽  
pp. 150-159 ◽  
Author(s):  
L. Kepka ◽  
D. Tyc-Szczepaniak ◽  
K. Osowiecka ◽  
A. Sprawka ◽  
B. Trąbska-Kluch ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Randomized Trial ◽  
Whole Brain Radiotherapy ◽  
Whole Brain ◽  
Tumor Bed ◽  
Brain Radiotherapy

Quality of life in patients with limited (1–3) brain metastases undergoing stereotactic or whole brain radiotherapy

2019 ◽  
Vol 196 (1) ◽  
pp. 48-57 ◽  
Author(s):  
Diana Steinmann ◽  
◽  
Dirk Vordermark ◽  
Wiebke Gerstenberg ◽  
Raimund Aschoff ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Brain Metastases ◽  
Whole Brain Radiotherapy ◽  
Whole Brain ◽  
Brain Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document